Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

RZLT

Rezolute Inc

May 23 • 10:56AM ET

2.84

Dollar change +0.03
Percentage change 1.07	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFAT DFAS DFAC

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	22.84%	Shs Outstand	36.83M	Perf Week	10.94%
Market Cap	114.00M	Forward P/E	-	EPS next Y	-0.80	Insider Trans	84.34%	Shs Float	30.97M	Perf Month	-1.73%
Income	-58.21M	PEG	-	EPS next Q	-0.31	Inst Own	67.62%	Short Float	1.02%	Perf Quarter	65.12%
Sales	0.00M	P/S	-	EPS this Y	-16.55%	Inst Trans	-0.33%	Short Ratio	0.61	Perf Half Y	253.06%
Book/sh	1.77	P/B	1.61	EPS next Y	32.40%	ROA	-52.46%	Short Interest	0.31M	Perf Year	38.54%
Cash/sh	1.99	P/C	1.42	EPS next 5Y	-	ROE	-58.75%	52W Range	0.72 - 3.72	Perf YTD	186.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.08%	ROI	-80.09%	52W High	-23.66%	Beta	1.21
Dividend TTM	-	Quick Ratio	11.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	294.44%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	11.82	EPS Y/Y TTM	-6.90%	Oper. Margin	0.00%	RSI (14)	51.61	Volatility	17.59% 12.11%
Employees	51	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	-10.10%	Payout	-	Rel Volume	3.16	Prev Close	2.81
Sales Surprise	-	EPS Surprise	-12.81%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	519.96K	Price	2.84
SMA20	0.53%	SMA50	8.74%	SMA200	85.58%	Trades		Volume	426,742	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire)
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
04:05PM	Loading…
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
04:05PM	Loading…
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire)
May-04-22 04:01PM	Rezolute to Host Corporate Update Call on May 4, 2022 (GlobeNewswire)
09:33AM	Rezolute, Inc. Announces Closing of Registered Direct Offering (GlobeNewswire)
May-01-22 11:25PM	Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (GlobeNewswire)
02:00PM	Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism (GlobeNewswire)
Apr-26-22 04:05PM	RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022 (GlobeNewswire) -7.74%
Mar-29-22 07:00AM	Rezolute Joins the Rare Disease Company Coalition (GlobeNewswire) -8.72%
Mar-23-22 07:00AM	Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +7.34%
Feb-22-22 07:00AM	Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME (GlobeNewswire) -6.18%
Feb-09-22 04:05PM	Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire)
Nov-12-21 04:05PM	Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-19-21 12:14PM	Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares? (Simply Wall St.)
Oct-13-21 08:10AM	Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering (GlobeNewswire) -14.19%
Oct-12-21 04:05PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering (GlobeNewswire)
Sep-22-21 04:05PM	Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 (GlobeNewswire)
Sep-15-21 04:56PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Sep-09-21 04:05PM	Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism (GlobeNewswire)
Sep-07-21 04:05PM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +5.41%
Aug-10-21 07:00AM	Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolutes Oral PKI for Treatment of DME (GlobeNewswire) +6.37%
Aug-03-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Jun-28-21 07:00AM	Rezolute Added to Russell Microcap® Index (GlobeNewswire)
Jun-24-21 09:01PM	Oppenheimer Bets on These 2 Stocks; Sees at Least 80% Upside Ahead (TipRanks)
Jun-03-21 05:35AM	Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely? (Simply Wall St.)
May-31-21 10:17AM	3 Strong Buy Stocks with 100% Upside Potential (TipRanks)
May-27-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +40.31%
May-20-21 07:00AM	Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs (GlobeNewswire)
May-18-21 07:00AM	Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board (GlobeNewswire)
May-17-21 04:05PM	Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
07:00AM	Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit (GlobeNewswire)
May-04-21 08:00AM	Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema (GlobeNewswire)
Apr-19-21 08:00AM	Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners (GlobeNewswire)
Mar-22-21 08:00AM	Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021 (GlobeNewswire)
Mar-08-21 08:00AM	Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts (GlobeNewswire) +24.96%
Mar-02-21 05:16PM	Rezolute to Participate in Upcoming Investor Conferences in March (GlobeNewswire) -5.34%
Feb-10-21 04:05PM	Rezolute Reports Second Quarter Fiscal 2021 Financial Results (GlobeNewswire) -9.07%
Jan-12-21 08:30AM	Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema (GlobeNewswire) +6.84%
Jan-11-21 07:56AM	What Is The Ownership Structure Like For Rezolute, Inc. (NASDAQ:RZLT)? (Simply Wall St.) -6.15%
Dec-28-20 04:05PM	Rezolute Announces Change of Transfer Agent (GlobeNewswire)
Dec-03-20 08:00AM	FDA Clears Rezolutes IND Application for RZ402 (GlobeNewswire) +7.64%
Nov-19-20 08:00AM	Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-05-20 08:00AM	Rezolute Announces Uplisting to the Nasdaq Capital Market (GlobeNewswire) +11.11%
Oct-09-20 08:30AM	Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq (GlobeNewswire) +8.75%
Sep-10-20 08:00AM	Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors (GlobeNewswire)
Jul-27-20 08:00AM	Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism (GlobeNewswire)
Jun-15-20 08:30AM	Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science (GlobeNewswire) -10.58%
May-28-20 08:30AM	Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting (GlobeNewswire)

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 28 '24	Buy	2.55	500	1,275	1,076	Mar 29 11:08 AM
Evans Daron	CFO	Mar 15 '24	Buy	1.69	20,000	33,830	20,000	Mar 19 09:17 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 14 '24	Buy	1.88	10,000	18,800	10,000	Mar 18 11:20 AM
Evans Daron	CFO	Mar 08 '24	Buy	1.93	50,000	96,345	120,900	Mar 08 12:37 PM
Kim Young-Jin	Director	Mar 07 '24	Buy	1.91	36,503	69,859	115,450	Mar 14 10:35 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 07 '24	Buy	1.85	500	925	500	Mar 11 10:35 AM
Elam Nevan C	CEO	Feb 26 '24	Buy	1.68	5,000	8,400	7,817	Feb 28 11:40 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 26 '24	Buy	1.70	2,000	3,400	42,552	Feb 27 08:47 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 23 '24	Buy	1.69	6,000	10,140	40,552	Feb 27 08:47 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.30	41,900	54,411	70,900	Feb 20 07:01 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.37	9,000	12,330	4,500	Feb 20 07:01 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 16 '24	Buy	1.31	7,000	9,142	34,552	Feb 21 11:55 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jul 03 '23	Buy	1.90	5,000	9,500	27,552	Jul 06 11:18 AM

Open in Screener

SVRA

Savara Inc

May 23 • 10:56AM ET

4.22

Dollar change -0.11
Percentage change -2.42	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO IWC ONEQ ITOT SBIO

Index	RUT	P/E	-	EPS (ttm)	-0.38	Insider Own	47.41%	Shs Outstand	138.14M	Perf Week	-10.49%
Market Cap	583.85M	Forward P/E	-	EPS next Y	-0.42	Insider Trans	-0.29%	Shs Float	72.68M	Perf Month	-0.35%
Income	-64.49M	PEG	-	EPS next Q	-0.11	Inst Own	46.09%	Short Float	5.92%	Perf Quarter	-17.48%
Sales	0.00M	P/S	-	EPS this Y	-25.54%	Inst Trans	2.91%	Short Ratio	4.93	Perf Half Y	13.27%
Book/sh	0.88	P/B	4.79	EPS next Y	-2.07%	ROA	-44.84%	Short Interest	4.30M	Perf Year	65.69%
Cash/sh	1.04	P/C	4.08	EPS next 5Y	-	ROE	-58.59%	52W Range	2.46 - 5.70	Perf YTD	-10.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.09%	ROI	-43.49%	52W High	-25.88%	Beta	0.70
Dividend TTM	-	Quick Ratio	14.90	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	71.75%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	14.90	EPS Y/Y TTM	-42.50%	Oper. Margin	0.00%	RSI (14)	40.22	Volatility	5.36% 6.19%
Employees	37	Debt/Eq	0.22	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	-61.22%	Payout	-	Rel Volume	1.56	Prev Close	4.33
Sales Surprise	-	EPS Surprise	-11.56%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	872.02K	Price	4.22
SMA20	-9.66%	SMA50	-11.36%	SMA200	-1.58%	Trades		Volume	354,025	Change	-2.42%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
04:05PM	Loading…
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Mar-06-24 04:05PM	Savara to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-02-24 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-31-24 08:05AM	Savara to Present at Two Upcoming Healthcare Conferences (Business Wire)
Dec-30-23 03:01PM	Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA) (GuruFocus.com)
Dec-21-23 08:05AM	Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
08:05AM	Loading…
Dec-20-23 08:05AM	Savara Added to the NASDAQ Biotechnology Index (Business Wire)
Dec-15-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Nov-21-23 08:05AM	Savara to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-09-23 04:05PM	Savara Reports Third Quarter Financial Results and Provides Business Update (Business Wire) -7.84%
Nov-08-23 04:05PM	Savara to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-06-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-27-23 07:29PM	3 Penny Stocks to Provide 1,000% Returns Over the Next Decade (InvestorPlace)
Sep-17-23 10:54AM	15 Penny Stocks with Biggest Upside (Insider Monkey)
Sep-12-23 09:12AM	The 3 Best Penny Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-05-23 04:05PM	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-10-23 04:05PM	Savara Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Aug-04-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jul-13-23 07:00AM	Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +8.92%
Jun-26-23 04:05PM	Savara Added to Russell 3000® Index (Business Wire) -7.34%
08:05AM	Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
08:05AM	Loading…
Jun-02-23 08:05AM	Savara to Present at the Jefferies Healthcare Conference (Business Wire)
May-28-23 08:26AM	Independent Director of Savara David Ramsay Buys 4.8% More Shares \ (Simply Wall St.)
May-16-23 12:32PM	Why Shares of Savara Jumped on Tuesday (Motley Fool) +9.09%
May-15-23 08:05AM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
May-05-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +6.84%
Apr-03-23 07:33AM	Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven In The Near Future (Simply Wall St.) -6.15%
Mar-31-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-30-23 04:05PM	Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update (Business Wire)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -7.31%
Mar-16-23 06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research)
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research) -15.94%
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 04:05PM	Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research) -7.42%
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 04:05PM	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research)
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research)
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research) +6.52%
06:24AM	Savara Inc. (NASDAQ:SVRA) insiders placed bullish bets worth US$858k in the last 12 months (Simply Wall St.)
Feb-14-23 08:05AM	Savara Announces New Leadership Appointments (Business Wire)
06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research)
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)
Feb-08-23 06:45AM	Daily Vickers Top Insider Picks for 02/08/2023 (Argus Research) -5.16%
Feb-07-23 06:46AM	Daily Vickers Top Insider Picks for 02/07/2023 (Argus Research)
Feb-06-23 06:56AM	Daily Vickers Top Insider Picks for 02/06/2023 (Argus Research)
Feb-03-23 06:32AM	Daily Vickers Top Insider Picks for 02/03/2023 (Argus Research)
Feb-02-23 06:43AM	Daily Vickers Top Insider Picks for 02/02/2023 (Argus Research) -5.20%
Feb-01-23 06:14AM	Daily Vickers Top Insider Picks for 02/01/2023 (Argus Research)
Jan-31-23 06:50AM	Daily Vickers Top Insider Picks for 01/31/2023 (Argus Research)
Jan-30-23 06:42AM	Daily Vickers Top Insider Picks for 01/30/2023 (Argus Research)
Jan-27-23 03:47PM	Why Shares of Savara Soared This Week (Motley Fool)
07:00AM	Daily Vickers Top Insider Picks for 01/27/2023 (Argus Research)
Jan-26-23 06:44AM	Daily Vickers Top Insider Picks for 01/26/2023 (Argus Research)
Jan-25-23 06:39AM	Daily Vickers Top Insider Picks for 01/25/2023 (Argus Research) +8.02%
Jan-24-23 06:48AM	Daily Vickers Top Insider Picks for 01/24/2023 (Argus Research) +8.72%
Jan-23-23 06:58AM	Daily Vickers Top Insider Picks for 01/23/2023 (Argus Research)
Jan-20-23 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
06:55AM	Daily Vickers Top Insider Picks for 01/20/2023 (Argus Research)
Jan-19-23 06:43AM	Daily Vickers Top Insider Picks for 01/19/2023 (Argus Research)
Jan-18-23 06:28AM	Daily Vickers Top Insider Picks for 01/18/2023 (Argus Research)
Jan-17-23 06:27AM	Daily Vickers Top Insider Picks for 01/17/2023 (Argus Research)
Jan-13-23 06:56AM	Daily Vickers Top Insider Picks for 01/13/2023 (Argus Research)
Jan-12-23 06:50AM	Daily Vickers Top Insider Picks for 01/12/2023 (Argus Research)
Jan-11-23 06:53AM	Daily Vickers Top Insider Picks for 01/11/2023 (Argus Research)
Jan-09-23 06:31AM	Daily Vickers Top Insider Picks for 01/09/2023 (Argus Research)
Jan-06-23 06:49AM	Daily Vickers Top Insider Picks for 01/06/2023 (Argus Research)
Jan-05-23 05:43AM	Private equity firms are Savara Inc.'s (NASDAQ:SVRA) biggest owners and were rewarded after market cap rose by US$25m last week (Simply Wall St.)
Jan-04-23 06:54AM	Daily Vickers Top Insider Picks for 01/04/2023 (Argus Research) +9.38%
06:54AM	Daily Vickers Top Buyers & Sellers for 01/04/2023 (Argus Research)
Jan-03-23 06:26AM	Daily Vickers Top Insider Picks for 01/03/2023 (Argus Research)
Dec-30-22 07:17AM	Daily Vickers Top Insider Picks for 12/30/2022 (Argus Research)
Dec-29-22 06:51AM	Daily Vickers Top Insider Picks for 12/29/2022 (Argus Research)
Dec-27-22 07:11AM	Daily Vickers Top Insider Picks for 12/27/2022 (Argus Research)
Dec-23-22 06:32AM	Daily Vickers Top Insider Picks for 12/23/2022 (Argus Research)
Nov-22-22 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elam Nevan C	Director	Dec 28 '23	Option Exercise	1.30	53,758	69,722	116,343	Dec 29 04:33 PM
Elam Nevan C	Director	Dec 28 '23	Sale	4.71	93,843	442,291	22,500	Dec 29 04:33 PM
Pauls Matthew	CHIEF EXECUTIVE OFFICER	Dec 28 '23	Sale	4.71	84,000	395,900	1,302,674	Dec 29 04:35 PM
Lowrance David L	CHIEF FINANCIAL OFFICER	Dec 28 '23	Sale	4.71	10,000	47,131	342,355	Dec 29 04:34 PM
Hawkins Richard J	Director	Dec 11 '23	Option Exercise	0.82	10,841	8,890	12,741	Dec 12 06:09 PM
Elam Nevan C	Director	Dec 11 '23	Option Exercise	0.82	10,841	8,890	40,085	Dec 12 06:08 PM
Chang Carmen	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:07 PM
Behbahani Ali	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:06 PM
BASKETT FOREST	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:05 PM
Growth Equity Opportunities 17	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:04 PM
Yang Rick	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:13 PM
SANDELL SCOTT D	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:11 PM
Walker Paul Edward	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:12 PM
Mathers Edward T	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:10 PM
Makhzoumi Mohamad	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:09 PM
Florence Anthony A. Jr.	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:08 PM
Pratt Raymond Dennis	Chief Medical Officer	Jun 26 '23	Buy	2.93	6,500	19,045	160,000	Jun 27 07:00 AM
RAMSAY DAVID A	Director	May 26 '23	Buy	2.63	37,124	97,599	2,201,142	May 26 11:31 AM
RAMSAY DAVID A	Director	May 25 '23	Buy	2.57	12,876	33,130	2,164,018	May 26 11:31 AM
RAMSAY DAVID A	Director	May 24 '23	Buy	2.56	50,000	127,800	2,151,142	May 26 11:31 AM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

RZLT

Rezolute Inc

SVRA

Savara Inc

Upgrade your FINVIZ experience